

Status: Currently Official on 16-Feb-2025  
Official Date: Official Prior to 2013  
Document Type: USP Monographs  
DocId: GUID-7B7E3E35-A2B6-4DFA-8EF7-41A4B1E603EF\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M66630\\_01\\_01](https://doi.org/10.31003/USPNF_M66630_01_01)  
DOI Ref: ks7si

© 2025 USPC  
Do not distribute

## Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution

» Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution is a sterile, isotonic, aqueous solution of Polymyxin B Sulfate and Trimethoprim Sulfate or of Polymyxin B Sulfate and Trimethoprim that has been solubilized with Sulfuric Acid. It contains not less than 90.0 percent and not more than 130.0 percent of the labeled amount of polymyxin B and the equivalent of not less than 90.0 percent and not more than 110.0 percent of the labeled amount of trimethoprim ( $C_{14}H_{18}N_4O_3$ ). It contains one or more preservatives.

**Packaging and storage**—Preserve in tight, light-resistant containers, and store at controlled room temperature.

**Labeling**—Label it to indicate that it is to be stored at 15° to 25°, protected from light.

### USP REFERENCE STANDARDS (11)—

[USP Polymyxin B Sulfate RS](#)

[USP Trimethoprim RS](#)

### **Identification**—

**A:** It meets the requirements for polymyxin B under *Thin-Layer Chromatographic Identification Test (201BNP)*.

**B:** The retention time of the trimethoprim peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the *Assay for trimethoprim*.

**STERILITY TESTS (71)**—It meets the requirements when tested as directed for *Membrane Filtration* under *Test for Sterility of the Product to be Examined*.

**pH (791):** between 4.0 and 6.2.

**Assay for polymyxin B**—Proceed as directed for polymyxin B under [Antibiotics—Microbial Assays \(81\)](#), using an accurately measured volume of Ophthalmic Solution, diluted quantitatively and stepwise with *Buffer B.6*, to obtain a *Test Dilution* having a concentration of polymyxin B assumed to be equal to the median dose level of the *Standard*.

### **Assay for trimethoprim**—

**Diluent**—Prepare a mixture of 0.01 N hydrochloric acid and acetonitrile (870:130).

**Mobile phase**—Dissolve 1.65 g of ethanesulfonic acid in 1000 mL of a mixture of water and acetonitrile (870:130). Adjust with 10 N sodium hydroxide or 0.1 N hydrochloric acid to a pH of 3.5. Pass this solution through a filter having a 0.5-μm or finer porosity, and degas. Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

**Standard preparation**—Dissolve an accurately weighed quantity of [USP Trimethoprim RS](#) in *Diluent* to obtain a solution having a known concentration of about 0.04 mg per mL.

**Assay preparation**—Transfer an accurately measured volume of Ophthalmic Solution, equivalent to about 1 mg of trimethoprim, to a 25-mL volumetric flask, dilute with *Diluent* to volume, and mix.

**Chromatographic system** (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 254-nm detector and a 3.9-mm × 30-cm column that contains packing L11. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the tailing factor is not more than 1.5, when calculated at 10% height of the peak; and the relative standard deviation for replicate injections is not more than 2.0%.

**Procedure**—Separately inject equal volumes (about 10  $\mu$ L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of trimethoprim ( $C_{14}H_{18}N_4O_3$ ) in each mL of the Ophthalmic Solution taken by the formula:

$$25(C/V)(r_u/r_s)$$

in which C is the concentration, in mg per mL, of [USP Trimethoprim RS](#) in the *Standard preparation*; V is the volume, in mL, of Ophthalmic Solution taken to prepare the *Assay preparation*; and  $r_u$  and  $r_s$  are the trimethoprim peak area responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

Topic/Question	Contact	Expert Committee
POLYMYXIN B SULFATE AND TRIMETHOPRIM OPHTHALMIC SOLUTION	<a href="#">Ying Han</a> Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	BIO42020 Biologics Monographs 4 - Antibiotics

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 28(4)

**Current DocID: GUID-7B7E3E35-A2B6-4DFA-8EF7-41A4B1E603EF\_1\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M66630\\_01\\_01](https://doi.org/10.31003/USPNF_M66630_01_01)**

**DOI ref: [ks7si](#)**

OFFICIAL